Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof

US12065505B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Joseph M. Luettgen · Princeton, US
• Lumelle Schneeweis · Sparta, US
• Ginger Rakestraw · Cambridge, US
• Christina Terragni · Wilmington, US
• Andrew K. Dilger · Princeton, US
• Jason Robert Pinckney · Westborough, US
• Steven Sheriff · Princeton, US
• Kevin Kish · Princeton, US
• Yongmi An · Princeton, US
• William R. Ewing · Yardley, US
• Stanley Krystek · Ringoes, US
• Aaron P. YAMNIUK · Lawrenceville, US

Key dates

• Filing date: Jan 7, 2022
• Grant date: Aug 20, 2024
• Expiry date: Jan 7, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.